CMPS Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

13.230

Open

11.750

VWAP

12.59

Vol

14.23M

Mkt Cap

1.75B

Low

11.560

Amount

179.24M

EV/EBITDA(TTM)

Total Shares

134.95M

1.32B

EV/OCF(TTM)

P/S(TTM)

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Events Timeline

(ET)

2026-07-07

16:00:00

Compass Pathways Announces 26-Week Results for COMP360

2026-07-02 (ET)

2026-07-02

10:00:00

Helus Pharma Reports FY26 Results with $157.3M Cash

News

9.0

07-07seekingalpha

PinnedCompass Pathways Releases New Data on COMP360 for Treatment-Resistant Depression

8.5

07-07Newsfilter

PinnedCOMP360 Shows Breakthrough Progress in Treatment-Resistant Depression

5.0

07-02Newsfilter

Compass Pathways Grants Equity Awards to New Employees

8.5

06-30Newsfilter

Rapid Growth in Major Depressive Disorder Treatment Market

5.0

06-29Globenewswire

Kailera Appoints New Chief Corporate Affairs Officer

8.5

06-26PRnewswire

Helus Pharma's HLP003 Phase 3 Trial Enrollment Surpasses 86%

7 Analyst Rating

Wall Street analysts forecast CMPS stock price to rise

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

8.00

Averages

18.43

High

40.00

Current: 0.000

Low

8.00

Averages

18.43

High

40.00

Wolfe Research

Rudy Li

Outperform

maintain

$18

AI Analysis

2026-07-07

New

Reason

Wolfe Research

Rudy Li

Price Target

$18

AI Analysis

2026-07-07

New

maintain

Outperform

Reason

Wolfe Research analyst Rudy Li said COMP006's durable 26-week data, improved responder/remission rates, and clean safety profile keep the NDA/1H27 launch on track. The firm views today's pullback as a sell-the-news overreaction and an attractive entry point. Wolfe Research told investors that it expects the stock to regain strong momentum after this pullback, though it will likely stay volatile ahead of NDA and regulatory updates. The firm reiterated an Outperform rating and $18 price target on Compass Pathways shares.

Morgan Stanley

Overweight

maintain

$17

2026-07-07

New

Reason

Morgan Stanley

Price Target

$17

2026-07-07

New

maintain

Overweight

Reason

Morgan Stanley notes that Compass Pathways reported COMP006 Part B 26-week data from its second Phase 3 pivotal trial of COMP360 in treatment-resistant depression, further bolstering the rapid and durable profile established across COMP005/006 trials thus far. The firm views the update as largely confirmatory with the key takeaway being consistency, as the 25mg dose continues to demonstrate rapid clinical effect, durability through 26 weeks, and a retreatment profile that supports a practical dosing paradigm in a highly chronic TRD population. A single incident of suicide was deemed not to be drug related, underscoring consistency within the drug's safety profile as well, adds Morgan Stanley. The firm has an Overweight rating on Compass with a price target of $17.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CMPS

Unlock Now

Valuation Metrics

The current forward P/E ratio for Compass Pathways PLC (CMPS.O) is 0.00, compared to its 5-year average forward P/E of -5.08. For a more detailed relative valuation and DCF analysis to assess Compass Pathways PLC's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.08

Current PE

0.00

Overvalued PE

-0.90

Undervalued PE

-9.27

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.04

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.54

Undervalued EV/EBITDA

-6.62

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

91.73

Current PS

30.54

Overvalued PS

488.85

Undervalued PS

-305.39

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Day trading stocks

Intellectia · 26 candidates

Region: USPrice: $5.00 - $80.00Price Change Pct: >= $5.00Relative Vol: >= 2List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000

Ticker

Name

Market Cap$

GFS

GlobalFoundries Inc

32.26B

UMC

United Microelectronics Corp

31.75B

SIRI

Sirius XM Holdings Inc

9.16B

HIMS

Hims & Hers Health Inc

7.07B

LEGN

Legend Biotech Corp

4.64B

BlackBerry Ltd

3.23B

what stocks have have hit pivot bottom

Intellectia · 247 candidates

Rsi Category: moderate, oversoldMoving Average Relationship: PriceAboveMA5Month Price Change Pct: $-45.00 - $-1.00Support Resistance Relationship: PriceAroundSupportMonthly Average Dollar Volume: >= 150,000

Ticker

Name

Market Cap$

LFCR

Lifecore Biomedical Inc

149.91M

NovaGold Resources Inc

3.54B

GLDG

GoldMining Inc

243.68M

CLPT

Clearpoint Neuro Inc

282.10M

PZG

Paramount Gold Nevada Corp

137.45M

CANF

Can Fite Biopharma Ltd

6.59M

Whales Holding CMPS

Deep Track Capital, LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Compass Pathways PLC (CMPS) stock price today?

The current price of CMPS is 12.99 USD — it has increased 1.17

What is Compass Pathways PLC (CMPS)'s business?

What is the price predicton of CMPS Stock?

Wall Street analysts forecast CMPS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CMPS is18.43 USD with a low forecast of 8.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.